CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, the expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell populations were phenotypically alike in dasatinib-treated CML patients, with a relatively balanced EM/E profile reflecting mean frequencies of ~40% for each subset in the TCR-Vβ+ fraction (Fig. 2B, right panel).